Curious....I agree it's hard to judge credibility when it comes to investing and talking to these companies. The way I've done it ...is after I have talked to other's in the past...I compare that experience and how the outcomes of their stocks have done to Peggy. All I can say...until I'm mislead...I have no reason to complain. She's not said anything to me that didn't come true....it's the time period that makes us frustrated. We all agree the company has good products...and like Paulie's comment to me one day was...I don't think McLaughlin would have gotten all those shares just to sell at that price of .40...He's going to help make this company work too!
Below is from a website from a newsletter... that shows their percentage of insider holdings...it says 67%..Hope that helps!
IRene
<Picture><Picture>Immudyne, Inc. P. O. Box 51507
Palo Alto, CA 94303
(415) 949-3864
F (415) 949-3961
------------------------------------------------------------------------
Charts| Research | Financials | Calendar | Press Releases | Search | Resources
Subscribe to Immudyne, Inc.'s E-mail Alert
------------------------------------------------------------------------
Immudyne, Inc.
FINANCIAL HIGHLIGHTS Industry:BiotechMarket Cap:$9.4 MSymbol:IMMD52 Wk Hi/Lo:$3.88 / 0.38L/T Debt:$030 Day Ave Vol:41,190Shares Out:20,000,000Est. Float:6,600,000Insider Hldgs:67%
February 27, 1997
HighLowCloseVolume0.470.410.479,700
Get a Current Quote on IMMD
------------------------------------------------------------------------
ImmuDyne Inc. is a research, development, manufacturing and marketing company. Its technology was developed as a result of research on immune stimulants and activators. The immune system's significance was highlighted by Nobel Prize winner Susumu Tonegawa of the Massachusetts Institute of Technology, who demonstrated that natural immune defenses can generate an almost limitless number of custom-made weapons to fight biological and chemical enemies. Stimulating and supporting that well-developed system thus has tremendous commercial significance in many areas. With combined worldwide sales in excess of $150 billion annually, the cosmetic, nutrition, aquaculture, pet care and pharmaceutical markets offer special opportunities as primary targets because they are substantial, growing and international. Health, nutrition, beauty and pet care are not seasonal; the market demand is constant and escalating. Aquaculture is a rapidly expanding industry with immediate needs for ImmuDyne products to help combat viral, bacterial, and environmental threats in order to improve survival rates of farmed seafood.
The major markets for ImmuDyne products are beauty, human health and nutrition, animal health and nutrition, aquaculture, and pharmaceuticals. All are growing and have tremendous new product opportunities. The health and beauty markets have no world boundaries. Although initial efforts were in the U.S., ImmuDyne is either selling or under negotiations for licensing and distribution agreements in several countries throughout the world. There is immediate opportunity in all of the developed countries. The following is a brief look at the size of these different markets. For a complete overview of Immudyne's products for these markets, visit Immudyne's Web Site.
Beauty Products
The largest segment of the cosmetic and toiletry market is skin care, primarily comprised of creams and lotions. This represents 38.5% of the total and is the fastest growing segment, advancing at a yearly rate of 11.9%. The overall category is projected to advance by 7.5% annually through 1998, by which time it will reach $14.4 billion.
Human Health and Nutrition
The multi-billion dollar industry of nutritional products is maturing as nutritional knowledge increases, general awareness develops, and alternatives to standard approaches to health are sought. This, combined with the demographics of the aging population, assures increasing demand for nutritional supplements to improve general health and well-being.
Animal Health and Nutrition
The entire pet market of dogs, cats, birds and tropical fish products is a $20 billion dollar market, of which pet food and treats constitute a $10 billion segment. The veterinary market is $5 billion, and pet accessories $5 billion. ImmuDyne technology can be applied within all of these categories in any number of products.
Aquaculture
The shrimp farming industry alone is estimated to be in excess of $2 billion worldwide. The entire aquaculture industry is over $4 billion worldwide. Disease has had a significant negative impact on the aquaculture industry, and ImmuDyne's IMMUSTIMT products can improve the survival and growth in cultured shrimp and fish populations challenged by pathogenic viruses and other microbes.
Pharmaceuticals
According to a major research firm, the market for biological and chemical substances that can stimulate, suppress or modulate human immune systems could be worth between $16 and $22 billion by the year 2000. On a percentage basis, this represents 17.7% of the pharmaceutical market.
------------------------------------------------------------------------
Information Archives
------------------------------------------------------------------------
Company Charts
SSNN makes available the trading history of the sponsor companies in its system. There are two options for the user:
Produce an on screen daily chart of trading data for the past year, complete with a 150-day exponential moving average; or
Produce an on screen weekly chart of the company's trading activity for the past 2-years, complete with a 30-week exponential moving average can be produced.
Go to top of page
------------------------------------------------------------------------
Up-To-Date Financial Data
Important instructions for using EDGAR.
Go to top of page
------------------------------------------------------------------------
Additional Information About Immudyne, Inc.
The following links will take the reader to other locations on theWeb presenting information on Immudyne, Inc. In many cases links back to SSNN are either not available, or not yet complete. We suggest you add SSNN to your bookmark list, or simply clicking the "back" arrowkey on your web browser:
Immudyne's Web SiteBullish Investor Article
Go to top of page
------------------------------------------------------------------------
Company Calendar
A calendar of important dates for Immudyne, Inc.. This listing includes dates for expected end of quarter and FY announcements,as well as a listing of PR Road Shows the company may hold.
Company Calendar Public Relations Shows
Go to top of page
------------------------------------------------------------------------
Press Releases
The following is a comprehensive listing of the companies press releases in a chronological order beginning with the most recent:
01/23/97IMMUDYNE ANNOUNCES YEAR END AND FIRST QUARTER RESULTS12/05/96IMMUDYNE ANNOUNCES AN AGREEMENT IN PRINCIPLE FOR SETTLEMENT OF SHAREHOLDER SUIT10/29/96IMMUDYNE ANNOUNCES ONGOING DISCUSSIONS BETWEEN PARTIES IN SHAREHOLDER LAWSUIT10/16/96IMMUDYNE, INC. PREPARES LAUNCH OF TWO NEW PRODUCTS FOR THE ORNAMENTAL FISH CARE MARKET08/20/96UNIVERSITY TESTS CONFIRM IMMUDYNE, INC. PRODUCTS EFFECTIVE IN PROTECTING SHRIMP AGAINST TAURA VIRUS WHICH HAS BEEN DEVASTATING THE FARMED SHRIMP INDUSTRY07/23/96IMMUDYNE, INC. ANNOUNCES SALES GROWTH AND NEW MARKETING PROGRAMS FOR NUTRITIONAL SUPPLEMENTS07/16/96IMMUDYNE ANNOUNCES RECORD YEAR-TO-DATE SALES06/11/96IMMUDYNE, INC. AND POSITIVE RESPONSE TELEVISION ANNOUNCE MARKETING AGREEMENT TO INTRODUCE A BREAKTHROUGH HEALTH AND BEAUTY SYSTEM06/03/96IMMUDYNE ANNOUNCES MARKETING OF CHOLESTEROL MANAGEMENT PRODUCT IN $2 BILLION CHOLESTEROL REDUCTION MARKET05/31/96IMMUDYNE ADOPTS RECOMMENDATIONS OF NEW AUDITING FIRM05/31/96IMMUDYNE ANNOUNCES ELECTION OF CHAIRMAN OF THE BOARD04/10/96IMMUDYNE ANNOUNCES "ALMOST A MILLION DOLLAR QUARTER"03/25/96IMMUDYNE SHAREHOLDERS ELECT NEW BOARD OF DIRECTORS WITH IMPRESSIVE QUALIFICATIONS03/08/96IMMUDYNE FOUNDER CONFIRMS COMMITMENT TO COMPANY GROWTH03/05/96IMMUDYNE ANNOUNCES PACIFIC EQUITIES' PURCHASE OF CONTROLLING INTEREST IN CARMEL RESEARCH, INC.02/20/96IMMUDYNE, INC. ANNOUNCES $4.5 MILLION AQUACULTURE CONTRACT WITH TEPUAL S.A.02/16/96IMMUDYNE, INC. ANNOUNCES INCREASED STAFFING FOR MANAGEMENT OF NEW BUSINESS OPPORTUNITIES01/16/96IMMUDYNE, INC. ANNOUNCES FIRST QUARTER RESULTS WITH SIGNIFICANT INCREASES IN SALES AND PROFITS
Go to top of page
------------------------------------------------------------------------
Print | Help Index | What's New! | Search | Research | Quotes | Links | E-mail SSNN.
------------------------------------------------------------------------
The information contained within the Small Stock News Network was obtained from sources we believe to be reliable, but it is not guaranteed by us, is not considered inclusive, and should not be relied upon as the sole source of information when making investement decisions. All written descriptions, and press releases are provided by the sponsor companies, and presented unedited. The information presented by the Small Stock News Network may be reproduced.
------------------------------------------------------------------------
c SSNN, 1995. All rights reserved.
. |
